🚨 There’s still time! 🚨
Don’t miss your chance to weigh in on the 1L treatment choice for HR+, HER2- #BreastCancer. 📊 Participate in the poll and join the discussion with your peers!

🔔 Vote now before it closes:
#BreastCancer